| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 9th February 2021 | Michael J. Mc Elhaugh | 20,000 | Open or private sale | $5.00 | $100,000.00 |
| 14th December 2020 | Michael J. Mc Elhaugh | 30,000 | Open or private sale | $5.00 | $150,000.00 |
| 14th December 2020 | Michael J. Mc Elhaugh | 10,000 | Open or private sale | $5.00 | $50,032.00 |
| 23rd July 2020 | Michael J. Mc Elhaugh | 20,000 | Open or private sale | $5.01 | $100,200.00 |
Arbutus Biopharma
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
Ticker: ABUS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1447028
Employees: 80
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $7 Th for the period Apr 2020 to Jun 2020 in the context of all up
Restructuring Charges of $64 Th for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $266 Th for the period Apr 2019 to Jun 2019 in the context of all up
Restructuring Charges of $149 Th for the period Jan 2019 to Jun 2019 in the context of all up
Revenue From Related Parties of $73 Th for the period Apr 2019 to Jun 2019 in the context of Genevant sciences corporation
Revenue From Related Parties of $189 Th for the period Jan 2019 to Jun 2019 in the context of Genevant sciences corporation
Fundamentals
Cash at Carrying Value: $46 M (44%)
Assets, Current: $86 M (-8%)
Property, Plant and Equipment, Net: $8 M (-10%)
Other Assets, Noncurrent: $173 Th (-40%)
Assets: $98 M (-7%)
Liabilities, Current: $6 M (-19%)
Liabilities: $32 M (-2%)
Common Stock, Value, Issued: $916 M (1%)
Common Stock, Shares, Issued: $71 M (9%)
Retained Earnings (Accumulated Deficit): $1 B (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $48 M (0%)
Stockholders' Equity (Parent): $66 M (0%)
Liabilities and Equity: $98 M (-7%)
Research and Development: $10 M (-49%)
General and Administrative Expenses: $4 M (-49%)
Restructuring Charges: $7 Th (-89%)
Operating Income/Loss: $13 M (-50%)
Other Income, net: $946 Th (-43%)
News
Cardiff Oncology: Can They Succeed Where Others Have Failed?
25th February 2021
Marketplace Contributors 2021 Top Ideas - Part 2
2nd February 2021